171046-94-9

Upstream product

• 141-97-9 ethyl acetoacetate 
• 5000-65-7 2-bromo-3'-methoxyacetophenone 
• 930-30-3 cyclopent-2-enone 
• 10365-98-7 3-methoxyphenylboronic acid 
• 95149-16-9 tris-(3-methoxy-phenyl)-bismuthane 
• 2398-37-0 3-methoxyphenyl bromide 

Downstream Products

• 118298-41-2 3-(3-methoxyphenyl)cyclopentane-1,1-dicarboxylic acid 
• 171046-99-4 3-(3-methoxyphenyl)cyclopentanecarboxylic acid 

Relevant academic research and scientific papers

5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV

The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

Tricyclic Sulfoxide-Alkene Hybrid Ligands for Chiral Rh(I) Complexes: The "Matched" Diastereomer Catalyzes Asymmetric C-C Bond Formations

Deprotonation of phenyldibenzo[b,f]tropylidene (8) with LDA/t-BuOK followed by quenching with either diastereomer of inexpensive glucose-based t-Bu-sulfinate (R)- or (S)-11 affords a sulfoxide-alkene hybrid ligand as the diastereomeric pairs (SS,SC)-9/(SS,RC)-10 and (RS,RC)-9/(RS,SC)-10, respectively, which via chromatographic/recrystallization may be separated into the four isomers. The optically pure diastereomeric ligands (SS,SC)-9 and (SS,RC)-10 react with [RhCl(coe)2]2 to form the dinuclear complexes (RS,SC)-11 and (RS,RC)-12, respectively, in which the bidentate ligands coordinate the metal centers through the sulfur and alkene donor functions. These complexes catalyze the conjugate addition of arylboronic acids to cyclic Michael acceptors with enantioselectivities of up to 99% ee. DFT calculations show the preponderant influence of planar chirality of the ligand alkene function. The enantioselectivity switch observed between (RS,SC)-11 and (RS,RC)-12 is explained by the inverted cis-trans coordinations of the substrate molecules in catalytic steps.

Rh-catalyzed 1,4-addition of triallyl(aryl)silanes to α,β-unsaturated carbonyl compounds

Rh-catalyzed 1,4-addition of triallyl(aryl)silane to α,β-unsaturated carbonyl compounds was developed. Triallyl(aryl)silanes were used as air- and moisture-stable silicon nucleophiles. Allylsilanes were converted to silanols in situ and underwent transmetalation. This method can accept a wide range of functionalized triallyl(aryl)silane and α,β-unsaturated carbonyl compounds.

Room-temperature rhodium-catalyzed asymmetric 1,4-addition of potassium trifluoro(organo)borates

For the first time the room-temperature rhodium-catalyzed asymmetric 1,4-addition of potassium aryltrifluoroborates to αβ-unsaturated substrates is described. Thanks to the use of a chiral diene as ligand for rhodium and triethylamine as base, to facilita

C1-symmetric monosubstituted chiral diene ligands in asymmetric rhodium-catalyzed 1,4-addition reactions

One trumps two: Monosubstituted chiral bicyclo[2.2.2]octadiene ligands, derived from carvone, form complexes with rhodium to catalyze the asymmetric addition of boronic acid substrates to α,β-unsaturated ketones (see scheme). The 1,4-adducts are produced

Enantioselective 1,4-addition of arylboronic acids to α,β-unsaturated carbonyl compounds catalyzed by rhodium(I)-chiral phosphoramidite complexes

A chiral bidentate phosphoramidite (5a) was synthesized from Shibasaki's linked-(R)-BINOL and P(NMe2)3 as a new ligand for rhodium(I)-catalyzed asymmetric 1,4-addition of arylboronic acids to α,β-unsaturated carbonyl compounds. The effects of 5a and Feringa's monodentate phosphoramidite (4, R1, R2 = Et) on the yields and enantioselectivities were fully investigated. The reaction was significantly accelerated in the presence of a base such as KOH and Et3N, allowing the reaction to be completed at the lower temperatures than 50 °C. The addition to cyclic enones such as 2-cyclopentenone, 2-cyclohexenone and 2-cycloheptenone at 50 °C in the presence of an [Rh(coe)2Cl]2-4 (R1, R2 = Et) complex resulted in enantioselectivities up to 98%, though it was less effective for acyclic enones (0-70% ee). On the other hand, a complex between [Rh(nbd)2]BF4 and 5a completed the addition to cyclic enones within 2 h at room temperature in the presence of Et3N with 86-99% yields and 96-99.8% ee. This catalyst was also effective for acyclic enones, resulting in 62-98% yields and 66-94% ee. The 1,4-additions of arylboronic acids to unsaturated lactones and acyclic esters with rhodium(I)-phosphoramidites complexes were also investigated.

Asymmetric 1,4-addition of triarylbismuths to enones catalyzed by dicationic palladium(II) complexes

A 1,4-addition of triarylbismuths to cyclic and acyclic enones was carried out in aqueous methanol in the presence of a chiral phosphine-dicationic palladium(II) complex. Palladium complexes of (S,S)-chiraphos or (S,S)-dipamp gave optically active β-arylketones of up to 95% ee.

Phenylethanolamine compounds useful as beta 3 agonists, process for producing the same, and intermediates in the production of the same

PCT No. PCT/JP96/03097 Sec. 371 Date Apr. 24, 1998 Sec. 102(e) Date Apr. 24, 1998 PCT Filed Oct. 24, 1996 PCT Pub. No. WO97/15549 PCT Pub. Date May 1, 1997The present invention relates to phenylethanolamine compounds represented by general formula [I]: (where R1 represents hydrogen or halogen; R2 represents hydrogen, hydroxy, lower alkoxy, lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups, lower alkoxy substituted with lower alkylaminocarbonyl which may be substituted with lower alkoxy, lower alkoxy substituted with cyclic aminocarbonyl of 4 to 6 carbon atoms, lower alkoxycarbonyl or carboxy; R3 represents hydrogen, hydroxy, lower alkoxy or lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups; R2 and R3 may be bonded to each other to form methylenedioxy substituted with carboxy or lower alkoxycarbonyl; and m and n are 0 or 1), and their pharmacologically acceptable salts, which have a potent beta 3 adrenergic stimulating effect and high beta 3 adrenergic receptor selectivity, as well as to processes for their production and intermediates in their production.

4,5-diaryloxazole derivatives

Heterocyclic compounds of the formula: whereinR1 is carboxy or protected carboxy, R2 is aryl which may have suitable substituent(s), R3 is aryl which may have suitable substituent(s), A1 is lower alkylene, A2 is bond or lower alkylene and -Q- is etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.

Conformationally Restricted and Conformationally Defined Tyramine Analogues as Inhibitors of Phenylethanolamine N-Methyltransferase

In a search for a selective inhibitor for the epinephrine synthesizing enzyme phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28), phenolic 2-aminotetralins (12-15 as conformationally restricted analogues of tyramine) and phenolic benzobicyclo3.2.